Credit: Shutterstock

While a small sam­pling, BIO's third di­ver­si­ty re­port pro­vides 'bench­mark' for da­ta-fo­cused in­dus­try to fur­ther an­a­lyze

The num­bers are some­what in and biotech di­ver­si­ty looks rel­a­tive­ly sim­i­lar to what it has been for years.

A 2021 sam­pling paints a very lim­it­ed pic­ture of the in­dus­try, with BIO’s third an­nu­al di­ver­si­ty re­port in­clud­ing on­ly 99 re­spon­dent com­pa­nies. Most ques­tions were not or could not be an­swered by every sin­gle or­ga­ni­za­tion, mean­ing many went unan­swered, such as in­sight on board-lev­el de­mo­graph­ics.

Sheila Gu­jrathi

Nonethe­less, the sur­vey pro­vides a bench­mark for in­dus­try and its lead­ers to be­gin un­der­stand­ing, an­a­lyz­ing and con­tin­ue mon­i­tor­ing progress on DEI ini­tia­tives, Sheila Gu­jrathi, mem­ber of mul­ti­ple biotech boards and Or­biMed ven­ture ad­vi­sor, told End­points News.

“I ap­plaud the ef­forts. I think it’s great that we’re hav­ing this re­port and get­ting these sur­veys done and mak­ing an ef­fort to ad­dress this very im­por­tant top­ic for our in­dus­try,” Gu­jrathi said.

She and oth­ers, in­clud­ing Ang­ie You, asked if the sur­vey is a true rep­re­sen­ta­tion of the in­dus­try and whether there was se­lec­tion bias among the re­spon­dents.

Ang­ie You

“I tend to be an op­ti­mist but I won­der if those who did re­spond are more proac­tive about DEI which could lead to in­flat­ed di­ver­si­ty num­bers. For ex­am­ple, I’m sur­prised that women make up 20% of CEOs in our in­dus­try,” You, who sold her im­muno-on­col­o­gy biotech Amu­nix to Sanofi late last year, told End­points in an email.

Gu­jrathi and Tra­vere Ther­a­peu­tics CEO Er­ic Dube em­pha­sized biotech is a da­ta-dri­ven in­dus­try, and lead­ers will like­ly pour over the num­bers as a start­ing point.

“As a sci­ence-based in­dus­try we know the pow­er of da­ta. The an­nu­al BIO DEI re­port should serve as a cat­a­lyst for every biotech ex­ec­u­tive in or­der to achieve a more eq­ui­table world. We must now move from state­ments about DEI to ac­tions that re­flect our com­mit­ment,” Dube told End­points in an email.

Dube pre­vi­ous­ly told End­points he is work­ing with oth­er San Diego-area biotech lead­ers to start an OUT­bio chap­ter in the re­gion for the in­dus­try’s LGBTQ com­mu­ni­ty.

Er­ic Dube

Out of the 91 com­pa­nies, 84 re­port­ed da­ta on CEO gen­der. Men led 66 of the com­pa­nies and women led 17. Fifty of 71 CEOs were white, 10 were Asian, sev­en were His­pan­ic/Lat­inx and three were Black.

Shao-Lee Lin, CEO of Los An­ge­les-based Ace­lyrin, put bio­phar­ma’s num­bers in a broad­er con­text, not­ing a March 2021 Bloomberg re­port found 15% of top 500 pub­licly list­ed US com­pa­nies were led by women.

“Those num­bers un­der­score how much Amer­i­can in­dus­try must im­prove not on­ly to achieve greater di­ver­si­ty in the work­force but al­so to re­al­ize the promise of greater in­no­va­tion that di­verse tal­ent can con­tribute,” Lin told End­points in an email. “The 2022 BIO di­ver­si­ty re­port high­lights that de­spite its small size and short­er his­to­ry, the bio­phar­ma in­dus­try is mak­ing rel­a­tive­ly good progress in its DEI ef­forts. But we have a long way to go.”

Shao-Lee Lin

Di­ver­si­ty should be in­fused through­out the en­tire com­pa­ny, Lin, You and oth­er ex­ec­u­tives point­ed out.

Women com­prised 49% of over­all em­ploy­ee bases, across 36 com­pa­nies that re­port­ed such da­ta for the BIO sur­vey, con­duct­ed with non­prof­it think tank Co­qual.

“Rep­re­sen­ta­tion of non-bi­na­ry pro­fes­sion­als re­mained neg­li­gi­ble, as many or­ga­ni­za­tions do not yet col­lect da­ta about em­ploy­ees who iden­ti­fy out­side of the gen­der bi­na­ry of men and women,” the BIO re­port said.

Out of 39 com­pa­nies, women com­prised 34% of ex­ec­u­tive teams and men made up 66%. One-quar­ter of ex­ec­u­tive teams, out of 32 re­spon­dents, saw a de­crease in women in the C-suite from 2020. Ex­ec­u­tive teams were al­so large­ly white, at 72% of 31 re­spon­dents.

Work­ers were slight­ly more di­verse, with white em­ploy­ees com­pris­ing 56% of staff, Asian em­ploy­ees mak­ing up 21%, His­pan­ic/Lat­inx work­ers at 7% and Black em­ploy­ees at 6%. Na­tive Hawai­ian/Pa­cif­ic Is­land and Na­tive Amer­i­can/Alaskan Na­tive work­ers made up a to­tal of 0.6% of work­forces.

The re­port did not in­clude da­ta on oth­er de­mo­graph­ics, such as LGBTQ+ in­di­vid­u­als, though BIO not­ed 21% of re­spon­dents tracked LGBTQ iden­ti­ty of their em­ploy­ees, a jump from 10% in 2020.

“We again en­deav­ored to ex­plore sev­er­al ar­eas of in­ter­est, such as LGBTQ rep­re­sen­ta­tion and part­ner­ships with women-owned and/or mi­nor­i­ty-owned sup­pli­ers but did not have suf­fi­cient­ly high re­sponse rates to these ques­tions,” the re­port not­ed.

Jake Be­craft

Jake Be­craft, CEO of Strand Ther­a­peu­tics, said founder-led biotechs could help pave the way for a more di­verse in­dus­try go­ing for­ward. He not­ed in­vestors and lead­ers in the in­dus­try will of­ten say man­age­ment needs to have “gray hair.”

“These are of course broad strokes, but what is im­por­tant to note is that any time there is a small col­lec­tion of de­ci­sion mak­ers at the top, and those peo­ple rough­ly come from the same back­grounds, they will pat­tern match to more of the same. Time to shake the mold,” Be­craft said.

No­tably, the re­port on­ly in­clud­ed re­sults from 99 com­pa­nies out of an in­dus­try that in­cludes thou­sands of bio­phar­mas. Most of the re­spond­ing com­pa­nies are based in the US, at 85%, and a few are lo­cat­ed in Eu­rope, Asia, Cana­da, Aus­tralia and South Amer­i­ca. No bio­phar­mas from Africa were in­clud­ed.

Be­craft said he was un­sure if com­pa­nies like his had re­ceived the sur­vey when it was be­ing con­duct­ed from No­vem­ber 2021 to Jan­u­ary 2022.

Michelle Mc­Mur­ry-Heath

“BIO is com­mit­ted to en­sur­ing that all peo­ple are able to par­tic­i­pate in – and ben­e­fit from – the biotech in­dus­try’s ef­forts to cure pa­tients, pro­tect the cli­mate, and nour­ish hu­man­i­ty,” BIO pres­i­dent and CEO Michelle Mc­Mur­ry-Heath said in a state­ment. “This com­mit­ment be­gins with en­sur­ing that the work­force re­flects those our in­dus­try serves. We have more work to do, and BIO plays an im­por­tant role as a thought leader and re­source for the biotech­nol­o­gy in­dus­try.”

Gu­jrathi said BIO is of­fer­ing to pro­vide ed­u­ca­tion­al and best prac­tices re­sources for bio­phar­mas look­ing to in­crease their DEI ef­forts and the in­dus­try ex­ec­u­tive be­lieves di­ver­si­ty, eq­ui­ty and in­clu­sion are “com­ing more to the fore­front.”

More aware­ness is com­ing thanks to stats sim­i­lar to the ones cit­ed in the BIO re­port, Gu­jrathi said. She, You and oth­ers have brought to­geth­er more than 100 fe­male ex­ec­u­tives in drug de­vel­op­ment over the past few months, in­clud­ing a March re­treat, and are sprout­ing up re­gion­al events to net­work and build up spon­sor­ship of fel­low fe­male lead­ers. Some mem­bers of the group, which Gu­jrathi refers to as the “biotech sis­ter­hood,” are com­ing to­geth­er Wednes­day night for din­ner on the out­skirts of the BIO con­ven­tion, she said.

In ad­di­tion to shar­ing in­dus­try stats, the re­port in­clud­ed DEI com­mu­ni­ca­tion strate­gies and rec­om­men­da­tions for ramp­ing up DEI. Com­mu­ni­ca­tion can oc­cur via quar­ter­ly town halls, month­ly emails and out­reach di­rect­ly from CEOs and oth­er ex­ec­u­tives, the re­port not­ed. For broad­er DEI ef­forts, da­ta should be col­lect­ed, tracked and shared.

Pay eq­ui­ty, in­ter­sec­tion­al­i­ty, feed­back, spon­sor­ship and em­ploy­ee re­source groups should all be con­sid­ered as well, the re­port con­clud­ed.

Has the mo­ment fi­nal­ly ar­rived for val­ue-based health­care?

RBC Capital Markets’ Healthcare Technology Analyst, Sean Dodge, spotlights a new breed of tech-enabled providers who are rapidly transforming the way clinicians deliver healthcare, and explores the key question: can this accelerating revolution overturn the US healthcare system?

Key points

Tech-enabled healthcare providers are poised to help the US transition to value, not volume, as the basis for reward.
The move to value-based care has policy momentum, but is risky and complex for clinicians.
Outsourced tech specialists are emerging to provide the required expertise, while healthcare and tech are also converging through M&A.
Value-based care remains in its early stages, but the transition is accelerating and represents a huge addressable market.

Alaa Halawaa, executive director at Mubadala’s US venture group

The ven­ture crew at Mubadala are up­ping their biotech cre­ation game, tak­ing care­ful aim at a new fron­tier in drug de­vel­op­ment

It started with a cup of coffee and a slow burning desire to go early and long in the biotech creation business.

Wrapping up a 15-year discovery stint at Genentech back in the summer of 2021, Rami Hannoush was treated to a caffeine-fueled review of the latest work UCSF’s Jim Wells had been doing on protein degradation — one of the hottest fields in drug development.

“Jim and I have known each other for the past 15 years through Genentech collaborations. We met over coffee, and he was telling me about this concept of the company that he was thinking of,” says Hannoush. “And I got immediately intrigued by it because I knew that this could open up a big space in terms of adding a new modality in drug discovery that is desperately needed in pharma.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Francesco Marincola, newly-appointed Sonata Therapeutics CSO

Kite's head of re­search leaves for Flag­ship start­up Sonata

Another leader is departing Kite Pharma, and will to spend the “last part” of his career exploring how cancer evades the immune system.

Kite’s senior VP and global head of cell therapy research Francesco Marincola left the Gilead CAR-T unit last week for Sonata Therapeutics. Flagship last May unveiled the startup, which was pieced together from two fledgling biotechs Inzen and Cygnal Therapeutics. As CSO, Marincola will lead Sonata’s push to reprogram cancer cells to make them more immunogenic.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.

Rohan Palekar, 89bio CEO

89bio’s PhII da­ta add to quick suc­ces­sion of NASH read­outs as field seeks turn­around

89bio said its drug was better than placebo at lessening fibrosis without worsening nonalcoholic steatohepatitis, or NASH, in two of three dose groups.

The San Francisco biotech said it thinks the Phase IIb data pave the way for a potential Phase III, following in the footsteps of another biotech in its drug class, Akero Therapeutics. To fund a late-stage study, CEO Rohan Palekar told Endpoints News 89bio “would need to raise additional capital,” with the company having about $188 million at the end of last year.

Flare Therapeutics biochemists Yong Li (L) and Valerie Vivat

A $123M Flare will get Third Rock on­col­o­gy biotech in­to the clin­ic this year

Flare Therapeutics will start its first human trial this year with an investigational urothelial cancer drug after pulling together a $123 million Series B from Big Pharmas, VCs and its incubator, Third Rock Ventures.

Launched in 2021 on the idea that a biotech could finally succeed at drugging the much-sought-after but stubborn transcription factor, Flare Therapeutics said Wednesday it is now primed for the clinic after closing its large financing haul earlier this year. The raise is a relatively stark figure in a tough startup financing environment but further buoys the upbeat signals coming out of other Third Rock biotechs in recent weeks, including the $200 million CARGO Therapeutics and $100 million Rapport Therapeutics rounds.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.

FDA in­di­cates will­ing­ness to ap­prove Bio­gen ALS drug de­spite failed PhI­II study

Ahead of Wednesday’s advisory committee hearing to discuss Biogen’s ALS drug tofersen, the FDA appeared open to approving the drug, newly released briefing documents show.

Citing the need for flexibility in a devastating disease like ALS, regulators signaled a willingness to consider greenlighting tofersen based on its effect on a certain protein associated with ALS despite a failed pivotal trial. The documents come after regulatory flexibility was part of the same rationale the agency expressed when approving an ALS drug last September from Amylyx Pharmaceuticals, indicating the FDA’s openness to approving new treatments for the disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.

Who are the women break­ing bar­ri­ers in drug de­vel­op­ment? Nom­i­nate them for End­points' an­nu­al re­port

Today, we’re opening nominations for our fifth annual Women in Biopharma R&D special report.

Over the last four years, we’ve honored 80 women whose extraordinary accomplishments have changed the game in biopharma R&D. We’re looking for big thinkers, scientists, executives and other enterprising women who are breaking barriers in drug development and inspiring the next generation of leaders.

Roche and Lil­ly team up to de­vel­op blood test to de­tect ear­ly signs of Alzheimer's

Eli Lilly is teaming up with Roche to help develop a blood test to detect early signs of Alzheimer’s disease and determine whether a patient should go for further confirmatory testing.

Roche’s Elecsys Amyloid Plasma Panel (EAPP) measures pTau 181 protein assay and APOE E4 assay in human blood plasma – elevations in pTau 181 are present in the early stages of Alzheimer’s, while the presence of APO E4 is the most common genetic risk factor for the disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.

Josep Bassaganya-Riera, NImmune Biopharma

Ex­clu­sive: Af­ter get­ting his drug back, Lan­dos founder as­sem­bles new start­up for the big PhI­II test

By the time Josep Bassaganya-Riera stepped down as founding CEO of Landos Biopharma in 2021, the company had racked up Phase II data for its top autoimmune program, completed what he called a positive end-of-Phase-II meeting with the FDA and plans to launch pivotal Phase III trials.

Since then, though, the new leaders at Landos have reshuffled their plans for the drug, omilancor, first announcing they will run a Phase IIb ahead of a Phase III and eventually shelving it altogether.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.